Der Gynäkologe

, 42:872 | Cite as

Neue Methoden zur Früherkennung der Präeklampsie

Leitthema

Zusammenfassung

Nach wie vor ist die Präeklampsie eine der häufigsten schwerwiegenden Schwangerschaftskomplikationen. Die Risikoabschätzung wird bis heute in der klinischen Routine vor allem durch die Risikofaktoren in der Anamnese bestimmt, und bis 2004 standen laut einer Veröffentlichung der WHO keine verlässlichen Parameter zur Prädiktion bereit. Neuere Biomarker, vor allem die Angiogenesefaktoren sFLT-1, „placental growth factor“ und Endoglin sowie „placental protein 13“, eröffnen aber, besonders in Kombination mit der Widerstandsmessung der A. uterina, erfolgversprechende Möglichkeiten zur Prädiktion der Präeklampsie. Auch die Genomforschung sowie die sog. Metabolomics und Proteomics zeigen neue mögliche Wege zum Verständnis von Pathomechanismen und Prädiktion. Im Beitrag soll versucht werden, die aktuellen Ergebnisse der Forschung und künftig mögliche Methoden zur Früherkennung von gefährdeten Patientinnen vorzustellen.

Schlüsselwörter

Präeklampsie Prädiktion Prävention Angiogenesefaktoren Biomarker 

New methods for early recognition of pre-eclampsia

Abstract

Pre-eclampsia remains one of the most common severe complications in pregnancy. Clinical assessment is still done primarily through risk factors ascertained by anamnesis. According to a World Health Organisation release, until 2004 there still existed no dependable parameters for estimation of the risk. More recently biomarkers, above all the angiogenesis factors sFLT-1, placental growth factor, endoglin, and placental protein 13, show promise for better prediction of pre-eclampsia, especially combined with uterine artery resistance measurements. Genome research and so-called metabolomics and proteomics introduce new ways of understanding the prediction and pathomechanics of this disorder. Recent study results and new developments for early recognition of endangered patients are presented.

Keywords

Pre-eclampsia Prediction Prevention Angiogenesis Biomarker 

Literatur

  1. 1.
    Sargent IL, Smarson AK (n d) Immunology of pre-eclampsia; current views and hypothesis. BIOS Scientific Publishers ltd., OxfordGoogle Scholar
  2. 2.
    Lee ES, Oh MJ, Jung JW et al (n d) The levels of circulating vascular endothelial growth factor and soluble FLT-1 in pregnancies complicated by preeclampsia. J Korean Med Sci 22:94–98Google Scholar
  3. 3.
    Hofmeyer GJ, Atallah AN, Duley L (n d) Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane datbase Syst Rev CD 001059Google Scholar
  4. 4.
    Poston L, Briley AL, Seed PT (2006) Vitamin C and vitamin E in pregnant women at risk for preeclampsia (VIP trial): randomised placebo-controlled trial. Lancet 367:1145–1154CrossRefPubMedGoogle Scholar
  5. 5.
    Duley L, Henderson-Amart DJ, Meher S, King JF (n d) Antiplatelet agents for preventing preeclampsia and ist complications (Review). Cochrane Database Syst Rev CD004659Google Scholar
  6. 6.
    Duckitt K, Harrington D (2005) Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies BMJ 330:565–567Google Scholar
  7. 7.
    Kaaja R (2008) Predictors and risk factors of pre-eclampsia. Minerva Ginecol 60(5):421–429PubMedGoogle Scholar
  8. 8.
    Jaccobsen B, Ladfors L, Milsom I (2004) Advanced maternal age an adverse perinatal outcome. Obstet Gynecol 104(4):727–733Google Scholar
  9. 9.
    Seoud MA, Nassar AH, Usta IM et al (2002) Impact of advanced maternal age on pregnancy outcome. Am J Perinatol 19(1):1–8CrossRefPubMedGoogle Scholar
  10. 10.
    Ziadeh S, Yahaya A (2001) Pergnancy outcome at age 40 and older. Arch Gynecol Obstet 265:30–33CrossRefPubMedGoogle Scholar
  11. 11.
    Pabinger I (2009) Thrombophilia and its impact on pregnancy. Thromb Res 123 (Suppl 3):S16–S21CrossRefPubMedGoogle Scholar
  12. 12.
    Conde-AgudeloA, Villar J, Lindenheimer M (2004) World Health Organisation systematic Review of screening tests for preeclampsia. Obstet Gynecol 104:1367–1391Google Scholar
  13. 13.
    Meads CA, Cnossen JS, Meher S, Khan KS et al (2008) Methods of prevdiction and prevention of pre-eclampsia:systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol Assess (Rockv) Vol 12:No 6Google Scholar
  14. 14.
    Carty DM, Delles CH, Dominiczak AF (2008) Novel biomarkers for predicting preeclampsia. Trends Cardiovasc Med 18:186–194CrossRefPubMedGoogle Scholar
  15. 15.
    Ong CY, Lash G, Parker PN (n d) Angiogenesis and placental growth in normal and compromised pregnancies. Best Pract Res Clin Obstet Gynecol 14:969–980Google Scholar
  16. 16.
    Cooper JC, Sharkey AM, Charnock-Jones DS et al (1996) VEGF mRNA levels in placentae from pregnancies complicated by preeclampsia. Br J Obstet Gynecol 103:1191–1196Google Scholar
  17. 17.
    Kim SY, Ryu HM, Yang JH et al (n d) Increased sFLT-1 to PlGF ratio in women who subsequently develop preeclampsia. J Kor Med Sci 22:873–877Google Scholar
  18. 18.
    Koga K, Osuga Y, Yoshino O et al (2003) Elevated Serum soluble Vascular Endothelial Growth Factor Receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 88:2348–2351CrossRefPubMedGoogle Scholar
  19. 19.
    Levine RJ, Maynard SE, Qian C et al (2004) Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350:672–683CrossRefPubMedGoogle Scholar
  20. 20.
    Stepan H, Geide A, Faber R (2004) Soluble fms-like tyrosine kinase 1. N Engl J Med 351:2241–2242CrossRefPubMedGoogle Scholar
  21. 21.
    Maynard SE, Min JY, Merchan J et al (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFLT-1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111:649–658PubMedGoogle Scholar
  22. 22.
    Venkatesha S, Toporsian M, Lam C et al (2006) Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 12:642–649CrossRefPubMedGoogle Scholar
  23. 23.
    Levine RJ, Lam C, Quian C et al (2006) Soluble endoglin and other circulating antiangiogenetic factors in preeclampsia. N Engl J Med 355:992–1005CrossRefPubMedGoogle Scholar
  24. 24.
    Rana S, Karumanchi SA, Levine RJ et al (2007) Sequential changes in antiangiogenetic factors in early pregnancy and risk of developing preeclampsia. Hypertension 50:137–142CrossRefPubMedGoogle Scholar
  25. 25.
    Stepan H, Unversucht A, Wessel N et al (2007) Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension 49:818–824CrossRefPubMedGoogle Scholar
  26. 26.
    Stepan H, Geipel A, Schwarz F et al (2008) Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion. Am J Obstet Gynecol 198:175e171–175e176CrossRefGoogle Scholar
  27. 27.
    Nicolaides KH, Bindra R, Turan OM et al (2006) A novel approach to first-trimester screening for early pre-eclampsia combinig serum PP13 and Doppler ultrasound. Ultrasound Obstet Gynecol 27:13–17CrossRefPubMedGoogle Scholar
  28. 28.
    Burger O, Pick E, Zwickel J et al (n d) Placental Protein 13: Effects on cultured trophoblasts, and ist detection in human body fluids in normal and pathological preganciesGoogle Scholar
  29. 29.
    Chafetz I, Kuhnreich I, Sammar M et al (2007) First trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction. Am J Obstet Gynecol 197:35e1–35e7CrossRefGoogle Scholar
  30. 30.
    Kenyon GL, DeMarini DM, Fuchs E et al (2002) Defining the mandate of proteomics in the post-genomic era: Workshop report. Mol Cell Proteomics 1:763–780PubMedGoogle Scholar
  31. 31.
    Zimmerli LU, Schiffer E, Zürbig P et al (2008) Urinary proteomic biomarkers in coronary artery disease. Moll Cell Proteomics 7:290–298CrossRefGoogle Scholar
  32. 32.
    Zhou H, Pisitkun T, Aponte A et al (2006) Exosomal fetuin a identified by proteomics: A novel urinary biomarker for detecting actute kidney injury. Kidney Int 70:1847–1857CrossRefPubMedGoogle Scholar
  33. 33.
    Daviss B (2005) Growing pains for metabolomics. Scientist 19:25–28Google Scholar
  34. 34.
    Brindle JT, Antti H, Holmes E et al (2002) rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using H-1-HMR-based metabolomics. Nature Med 8:1439–1444CrossRefPubMedGoogle Scholar
  35. 35.
    Brindle JT, Nicholson JK, Schofield PM et al (2003) Application of chemometrics to H-1-NMR spectroscopic data to investigate a relationship between human serum metabolic profiles and hypertension. Analyst 128:32–36CrossRefPubMedGoogle Scholar
  36. 36.
    Kenny LC, Dunn WB, Ellis DI et al (2005) Novel biomarkers for preeclampsia detected using metabolomics and machine learning. Metabolomics 1:227–234CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag 2009

Authors and Affiliations

  1. 1.Universitätsklinik für Frauenheilkunde, Abteilung für feto-maternale MedizinMedizinische Universität Wien, AKH-WienWienÖsterreich

Personalised recommendations